Ruocong Zhao

Title: Ruocong Zhao: Innovator in Chimeric Antigen Receptor Technology

Introduction

Ruocong Zhao is a prominent inventor based in Guangdong, China. He has made significant contributions to the field of biomedicine, particularly in the development of chimeric antigen receptors (CARs) for cancer treatment. His innovative work focuses on enhancing the efficacy of therapies targeting specific antigens.

Latest Patents

Ruocong Zhao holds a patent for a scFv amino acid sequence, which is capable of recognizing the CD19 antigen. This patent also includes a chimeric antigen receptor that incorporates this sequence, along with a nucleic acid encoding it. The application of this invention is particularly relevant in the manufacture of medicaments aimed at treating tumors. The chimeric antigen receptor developed by Zhao features at least one extracellular domain, an optional transmembrane domain, and at least one intracellular costimulatory signaling domain. This design has been humanized, leading to improved survival rates in vivo and extended complete remission periods for patients.

Career Highlights

Zhao is associated with Guangdong Zhaotai Invivo Biomedicine Co., Ltd., where he continues to advance his research and development efforts. His work is characterized by a commitment to innovation and a focus on practical applications in the medical field.

Collaborations

Zhao collaborates with notable colleagues, including Peng Li and Zhaoyang Tang, who contribute to his research initiatives and help drive forward the advancements in CAR technology.

Conclusion

Ruocong Zhao's contributions to the field of biomedicine, particularly through his patented innovations in chimeric antigen receptors, highlight his role as a key inventor in cancer treatment advancements. His work continues to pave the way for new therapeutic options for patients.